期刊文献+

单克隆抗体类生物制品关键质量属性 被引量:1

Critical quality attributes of monoclonal antibody-based biological products
下载PDF
导出
摘要 分析单克隆抗体(mAb)类生物制品关键质量属性(CQAs)及影响其杂质检测结果准确性、可靠性的因素。依据mAb类药物的特点及目标产品质量概况(QTPP)分析其关键质量属性。质量属性可分为关键的和非关键的:质量属性是否作为CQAs主要通过评价其超出可接受范围时对产品安全性和有效性的影响程度。mAb类药物CQAs包括等电点、单体、大小变异体、电荷变异体、N-糖基化修饰、唾液酸含量、生物学活性等。研究mAb类生物制品CQAs、分析其杂质检测结果准确可靠的影响因素对产品治疗控制和临床用药安全具有重要的价值。 To analyze the critical quality attributes(CQAs)of monoclonal antibody(mAb)based biological products and the factors that affect the accuracy and reliability of impurity detection results.Analyze the critical quality attributes of mAb drugs based on their characteristics and quality target product profile(QTPP).Quality attributes can be divided into critical and noncritical:whether quality attributes are considered CQAs mainly depends on evaluating their impact on product safety and effectiveness when they exceed the acceptable range.CQAs of mAb drugs include isoelectric points,monomers,size heterogeneities,charge heterogeneities,N-glycosylation modifications,sialic acid content,biological activity,etc.Studying the CQAs of mAb biological products and analyzing the factors that affect the accuracy and reliability of impurity detection results are of great value for product treatment control and clinical medication safety.
作者 景荣先 曾媛 张国林 JING Rongxian;ZENG Yuan;ZHANG Guolin(Pharmacy Department,the Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou Municipal Hospital,Jiangsu,Suzhou 215002,China;China Drug Research and Development Department,Clinical Pharmacology Department,Pfizer(China)Research and Development Co.,Ltd.,Shanghai 201203;Suzhou Institute for Drug Control,Jiangsu,Suzhou 215104,China)
出处 《中国医药科学》 2023年第18期177-180,共4页 China Medicine And Pharmacy
基金 江苏省市场监督管理局科技计划项目(KJ2023061) 江苏省苏州市科技计划项目(SYS2020199)。
关键词 单克隆抗体 杂质 质量 准确性 稳定性 Monoclonal antibody Impurities Quality Accuracy Stability
  • 相关文献

参考文献25

二级参考文献92

  • 1胡超,董立厚,王颖,韩敏,勾忠平,郑莉.2种注射用重组人甲状旁腺素健康人体生物等效性研究[J].中国新药杂志,2020,29(3):293-298. 被引量:2
  • 2范星宇,洪梦琴,杨敏.IL-6与类风湿关节炎的关系及作用机制的研究进展[J].世界最新医学信息文摘,2019,0(86):65-65. 被引量:12
  • 3李克坚,杨化新,梁成罡,徐康森.重组人甲状旁腺激素效价测定方法的研究[J].药物生物技术,2005,12(1):43-45. 被引量:4
  • 4SLIWKOWSKI MX, MELLMAN I. Antibody therapeutics in cancer [J]. Science, 2013, 341(6151): 1192-1198.
  • 5GAO K, WANG J. The biopharmaceutical industry in China: his- tory and future perspectives[J]. Front Med, 2012, 6(2) : 101 - 111.
  • 6LIU L. Antibody glycosylation and its impact on the pharmacoki- netics and pharmacodynamics of monoclonal antibodies and Fc-fu- sion proteins[J]. J Pharm Sci, 2015, 104(6) : 1866 -1884.
  • 7SHI HH, GOUDAR CT. Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans [ J]. Biotechnol Bioeng, 2014, 111(10) : 1907 -1919.
  • 8CHUNG CH, MIRAKHUR B, CHAN E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1, 3-galactose [J]. NEnglJMed, 2008, 358(11): 1109-1117.
  • 9RAJU TS. Terminal sugars of Fc glycans influence antibody effec- tor functions of IgGs [ J]. Curr Opin Immunol, 2008, 20 (4) : 471 - 478.
  • 10LIU SD, CHALOUNI C, YOUNG JC, et al. Afucosylated anti- bodies increase activation of FcgammaRIIIa-dependent signaling components to intensify processes px'omoting ADCC [ J]. Cancer Immunol Res, 2015, 3(2) : 173 -183.

共引文献46

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部